Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.625 USD | +7.55% | -0.15% | -26.59% |
Financials (USD)
Sales 2024 * | 223M | Sales 2025 * | 321M | Capitalization | 469M |
---|---|---|---|---|---|
Net income 2024 * | -284M | Net income 2025 * | -148M | EV / Sales 2024 * | 2.6 x |
Net Debt 2024 * | 112M | Net Debt 2025 * | 118M | EV / Sales 2025 * | 1.83 x |
P/E ratio 2024 * |
-1.76
x | P/E ratio 2025 * |
-3.66
x | Employees | 380 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.25% |
Latest transcript on Travere Therapeutics, Inc.
1 day | -2.84% | ||
1 week | -0.16% | ||
Current month | +11.39% | ||
1 month | +17.11% | ||
3 months | -25.87% | ||
6 months | +4.58% | ||
Current year | -31.48% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Dube
CEO | Chief Executive Officer | 51 | 19-01-03 |
Chris Cline
DFI | Director of Finance/CFO | 40 | 14-07-31 |
Jula Inrig
CTO | Chief Tech/Sci/R&D Officer | 49 | 22-01-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Coughlin
BRD | Director/Board Member | 57 | 15-03-30 |
Jeffrey Meckler
BRD | Director/Board Member | 57 | 14-10-07 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 20-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 6.6 | +7.14% | 719 633 |
24-05-24 | 6.16 | -2.84% | 591,865 |
24-05-23 | 6.34 | -3.35% | 1,147,369 |
24-05-22 | 6.56 | -0.76% | 811,497 |
24-05-21 | 6.61 | +7.13% | 1,389,666 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.48% | 469M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.46% | 22.1B | |
-8.52% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- TVTX Stock